Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Circulating Tumor DNA Directed Consolidation Durvalumab (MEDI4736) Following Induction and Concurrent Durvalumab with SABR for Stage I NSCLC. SCION: SABR and Checkpoint Inhibition of NSCLC

NCT04944173 is registered in ClinicalTrials.gov with University of British Columbia as lead sponsor.

NCT NCT04944173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04944173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Circulating Tumor DNA Directed Consolidation Durvalumab (MEDI4736) Following Induction and Concurrent Durvalumab with SABR for Stage I NSCLC. SCION: SABR and Checkpoint Inhibition of NSCLC
Lead sponsor
University of British Columbia
Phase
Phase 2
Overall status
Withdrawn
Start date
August 11, 2023
Completion date
June 30, 2027
Enrollment
0 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, lung adenocarcinoma, stage i, lung cancer, lung cancer stage i, lung squamous cell carcinoma stage i, non small cell lung cancer, non-small cell lung cancer stage i